|Articles|May 1, 2007
- Volume 0 0
MYLAN BARRED FROM SELLING GENERIC TOPAMAX
Advertisement
A federal judge in NewJersey issued an injunctionpermanently barringMylan Pharmaceuticalsfrom selling generic topiramatetablets and capsulesin the United Statesbefore September 26,2008, the expiration dateof the patent for TOPAMAX(topiramate) heldby Ortho-McNeil NeurologicsInc. Mylan hadchallenged the validity ofthat patent and filed anabbreviated new drugapplication to market ageneric version of theepilepsy drug. The brandedmanufacturer counteredwith a patentinfringement complaintagainst Mylan and obtaineda preliminary injunctionagainst the genericfirm last fall.
Articles in this issue
almost 19 years ago
can you READ these Rxs?almost 19 years ago
compounding HOTLINEalmost 19 years ago
Pseudoephedrine Logs Need Constant Tendingalmost 19 years ago
Another Federal Court Rejects a Drug Importation Planalmost 19 years ago
Home Infusion Therapy Gets Patients Out of the Hospitalalmost 19 years ago
RESPy AWARD: Teamwork Is the Thread That Bindsalmost 19 years ago
Child-resistant Does Not Mean Childproofalmost 19 years ago
ccpa SPEAKS OUT: CCPA Works to Improve Medicare Part Dalmost 19 years ago
Genetic Testing: Remarkable Resource or Invasion of Privacy?almost 19 years ago
case STUDIESNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5